Biological actions and therapeutic potential of the glucagon-like peptides.
about
Biology of Cholangiocytes: From Bench to BedsideThe pharmacological landscape and therapeutic potential of serine hydrolasesThe Pathogenesis of Resection-Associated Intestinal AdaptationAddition of dipeptidyl peptidase-4 inhibitors to sulphonylureas and risk of hypoglycaemia: systematic review and meta-analysisOlmesartan decreased levels of IL-1β and TNF-α, down-regulated MMP-2, MMP-9, COX-2, RANK/RANKL and up-regulated SOCs-1 in an intestinal mucositis modelResveratrol increases glucose induced GLP-1 secretion in mice: a mechanism which contributes to the glycemic controlIsolation, identification and biological activity of gastrin-releasing peptide 1-46 (oGRP 1-46), the primary GRP gene-derived peptide product of the pregnant ovine endometrium.Sensory nerves contribute to insulin secretion by glucagon-like peptide-1 in mice.Secretory units of islets in transplantation index is a useful clinical marker to evaluate the efficacy of sitagliptin in treatment of type 2 diabetes mellitus.Chronic inflammation and cytokines in the tumor microenvironment.Gut hormones, and short bowel syndrome: the enigmatic role of glucagon-like peptide-2 in the regulation of intestinal adaptation.Incretin effect of Urena lobata leaves extract on structure and function of rats islet β-cells.Glucagon-like peptide-1 synthetic analogs: new therapeutic agents for use in the treatment of diabetes mellitus.Prior short-term consumption of resistant starch enhances postprandial insulin sensitivity in healthy subjects.Prebiotic fiber modulation of the gut microbiota improves risk factors for obesity and the metabolic syndrome.Direct and indirect mechanisms regulating secretion of glucagon-like peptide-1 and glucagon-like peptide-2.Stimulation of glucagon-like peptide-1 receptor through exendin-4 preserves myocardial performance and prevents cardiac remodeling in infarcted myocardium.The delay in the development of experimental colitis from isomaltosyloligosaccharides in rats is dependent on the degree of polymerizationGLP-1 could improve the similarity of IPCs and pancreatic beta cells in cellular ultrastructure and function.Physiology of the aerodigestive system and aberrations in that system resulting in aspiration.Future considerations in aspiration pneumonia in the critically ill patient: what is not known, areas for future research, and experimental methods.Therapeutic concentrations of glucagon-like peptide-1 in cerebrospinal fluid following cell-based delivery into the cerebral ventricles of catsChanges in Adenosine Deaminase Activity in Patients with Type 2 Diabetes Mellitus and Effect of DPP-4 Inhibitor Treatment on ADA Activity.Patient considerations and clinical utility of a fixed dose combination of saxagliptin/metformin in the treatment of type 2 diabetesDipeptidyl-peptidase IV from bench to bedside: an update on structural properties, functions, and clinical aspects of the enzyme DPP IV.Glucagon-like peptide 1 agonists and the development and growth of pancreatic beta-cells.The synergistic effect of valsartan and LAF237 [(S)-1-[(3-hydroxy-1-adamantyl)ammo]acetyl-2-cyanopyrrolidine] on vascular oxidative stress and inflammation in type 2 diabetic mice.Efficacy and safety of sitagliptin for the treatment of diabetes mellitus complicated by chronic liver injuryIntestinotrophic glucagon-like peptide-2 (GLP-2) activates intestinal gene expression and growth factor-dependent pathways independent of the vasoactive intestinal peptide gene in miceEffect of glucagon-like peptide 2 on hepatic, renal, and intestinal disposition of 1-chloro-2,4-dinitrobenzeneMetabolic manifestations of insulin deficiency do not occur without glucagon action.Postprandial Hypoglycemia in Children after Gastric Surgery: Clinical Characterization and Pathophysiology.An emerging role of glucagon-like peptide-1 in preventing advanced-glycation-end-product-mediated damages in diabetesCirculating FGF21 proteolytic processing mediated by fibroblast activation protein.Jerusalem artichoke and chungkookjang additively improve insulin secretion and sensitivity in diabetic ratsEffect of weight loss by gastric bypass surgery versus hypocaloric diet on glucose and incretin levels in patients with type 2 diabetes.The ins and outs of secretion from pancreatic beta-cells: control of single-vesicle exo- and endocytosis.Is Glucagon-like peptide-1, an agent treating diabetes, a new hope for Alzheimer's disease?Exendin-4 induces myocardial protection through MKK3 and Akt-1 in infarcted heartsCombination therapy with glucagon-like peptide-1 and gastrin restores normoglycemia in diabetic NOD mice.
P2860
Q26738866-1643E13A-5C79-4937-A6B9-3EB92292F37BQ26995817-E60723F1-34EE-4C0C-BA21-BFB4509ABC6CQ28076127-D0968AB4-E193-4A09-B705-296601129D34Q28275281-307B1FE6-81E6-4CDE-B67A-D57AA4E60313Q28542802-84DCE428-D598-46B3-8428-C9F890DB9871Q28743932-C86FD820-3267-419B-A1E3-B9D9EE9DD8EDQ30925323-0774C9E7-728E-4CA5-A805-548AE3E37E4AQ33196495-B7D2C7CB-BC5B-4593-B510-E5424909D7FAQ33603545-14C1F5FA-DF9D-41E7-A212-76FAAEFFB5B6Q33678275-6A901036-EC9D-47B8-ACFA-ADB804921922Q33865971-84ABCEAB-77C3-44A0-A57B-96326E62C9E7Q33896508-EFBF5D6B-E168-4E33-B1ED-1DB841FA03FCQ34026346-A37560EA-6907-45B0-903F-FFE0ECA5B261Q34192590-B0FAAB27-2E5D-4F7D-A2A1-15A5736E8027Q34255464-F422DB8E-271A-4E21-A0CF-3CCA36E23C6BQ34289440-49DFD5CA-BA8C-4706-B9B9-B267FF7C8FFEQ34355984-E922ED8D-C3C3-4282-BD7A-DD85AE991469Q34500574-6C0B41E7-48DF-44E7-BD59-6729034A7C72Q34647309-700D1D24-6FCD-46A1-A354-366325D9AB78Q34983182-724514D1-5FA8-4DBA-9113-B77074D589E4Q34983228-B1D9128C-EE14-4A43-BD63-C0F592E9F594Q35044628-13CA9533-9D4A-440A-B2A1-EC388D931D76Q35067242-2C2BF8B4-97B7-4A09-8252-0CC4EE2086F1Q35115112-1EBC67C4-5DB8-45A2-9686-13A71FB6656EQ35189265-2EE453E0-5DAC-45A1-BFC6-5A0C6E683622Q35772023-CD68AB53-D2F0-4A06-A31B-079B9247048FQ35846052-CF04997C-832E-4B16-A994-3866C54FAC9EQ35849028-B5E5A7E6-1972-44EE-9440-39E7A68AF1B1Q35986076-ABB9B895-9DB7-403A-9B7C-99824193346CQ36057404-0075F32B-463A-4317-8049-F4EC16BC2830Q36236307-97F363CF-8C2E-472B-807A-B7D0ADD0268BQ36520647-2FFB2CF9-957A-4395-8228-67411DE69777Q36567296-C22CB28F-20AF-43D5-902D-EFE22BE39DE1Q36611366-8B53880A-1B30-442B-8F9C-1F6A62C5A894Q36614083-4A555C7D-476D-4F4B-8EFC-E511232250CFQ36755303-66F81422-F249-4F27-B126-33BFF2732D4FQ36786251-EFF42585-B3C8-48B0-AACC-6FCCEF638280Q36860616-F68EF8FB-AFA7-4B12-BC1C-64E75DFD791CQ36895565-6D0E98E2-2044-4E4B-A33F-FF24C620D513Q36975470-8DFB5E3A-7471-4991-A2CE-51745BEBD88B
P2860
Biological actions and therapeutic potential of the glucagon-like peptides.
description
2002 nî lūn-bûn
@nan
2002 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Biological actions and therapeutic potential of the glucagon-like peptides.
@ast
Biological actions and therapeutic potential of the glucagon-like peptides.
@en
Biological actions and therapeutic potential of the glucagon-like peptides.
@nl
type
label
Biological actions and therapeutic potential of the glucagon-like peptides.
@ast
Biological actions and therapeutic potential of the glucagon-like peptides.
@en
Biological actions and therapeutic potential of the glucagon-like peptides.
@nl
prefLabel
Biological actions and therapeutic potential of the glucagon-like peptides.
@ast
Biological actions and therapeutic potential of the glucagon-like peptides.
@en
Biological actions and therapeutic potential of the glucagon-like peptides.
@nl
P356
P1433
P1476
Biological actions and therapeutic potential of the glucagon-like peptides.
@en
P304
P356
10.1053/GAST.2002.31068
P407
P577
2002-02-01T00:00:00Z